

OLIVIER J. WOUTERS, PH.D.

Brown University • 121 South Main Street • Providence, RI 02903, USA
olivier_wouters@brown.edu • +1 401 863 2087

ACADEMIC APPOINTMENTS

- | | |
|--------------|--|
| 2025–present | Associate Professor (with tenure)
Department of Health Services, Policy, and Practice
Brown University |
| 2019–2024 | Assistant Professor
Director, M.Sc. Global Health Policy
Department of Health Policy
London School of Economics and Political Science |
| 2018–2019 | Fellow in Health Economics
Department of Health Policy
London School of Economics and Political Science |

EDUCATION

- | | |
|------|--|
| 2018 | Ph.D., Health Policy and Health Economics
London School of Economics and Political Science |
| 2012 | M.Sc., International Health Policy (Health Economics), with distinction
London School of Economics and Political Science |
| 2011 | B.Sc., Science, Technology & International Affairs, with honors (<i>cum laude</i>)
Edmund A. Walsh School of Foreign Service, Georgetown University |

AWARDS

- | | |
|------|--|
| 2025 | Publication-of-the-Year Award , AcademyHealth |
| 2023 | Prize for Best Paper (joint winner), Special Issue on Challenges in Implementing the U.S. Inflation Reduction Act, <i>Journal of Managed Care & Specialty Pharmacy</i> |
| 2021 | Excellence in Education Award , London School of Economics |
| 2013 | Young Forum Gastein Scholar |
| 2012 | Brian Abel-Smith Prize , highest marks in the M.Sc. in International Health Policy (Health Economics), London School of Economics and Political Science |

VISITING APPOINTMENTS

2025–present	Affiliated Faculty , Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Harvard Medical School, USA
2024–2025	Visiting Assistant Professor , Department of Medicine, Brigham and Women's Hospital, USA
2024	Visiting Scholar, Department of Health Services, Policy, and Practice, School of Public Health, Brown University, USA
2019–2020	Affiliated Faculty, Leuven Institute for Healthcare Policy, KU Leuven, Belgium
2015–2018	Visiting Research Fellow, Health Economics Unit, University of Cape Town, South Africa

GRANTS

PRINCIPAL INVESTIGATOR

2026–2028	PI, grant from Arnold Ventures to estimate the research and development investments required to bring a new medicine to market (\$399,981)
2025–2027	PI, grant from Arnold Ventures to study the impact of the Trump Administration's Most Favored Nation drug pricing plan (\$397,750)
2025–2026	PI, grant from the National Institute on Aging to study market failures in drug development for Alzheimer's disease (\$199,311)
2023	Co-PI (with Inmaculada Hernandez, UC San Diego), grant from the Commonwealth Fund to study US drug pricing reforms under the Inflation Reduction Act (\$148,656)
2021	PI, grant from the London School of Economics Research Support Fund to study drug prices and affordability in 87 countries (£20,000)

SUBCONTRACT PRINCIPAL INVESTIGATOR

2025	Subcontract PI, grant from Arnold Ventures to Brigham and Women's Hospital (PI: Aaron S. Kesselheim) to study U.S. pharmaceutical policy (\$49,767)
------	---

CO-INVESTIGATOR

2025	Co-Investigator (PI: S. Sean Tu, University of Alabama), grant from the Commonwealth Fund to study the impact of orphan drug exclusivities on generic and biosimilar competition (\$140,000)
------	--

SHORT-TERM CONSULTANCIES

2024–2025	World Bank
2023	World Health Organization Regional Office for Europe
2019	African Development Bank
2013–2017	World Bank
2014	World Health Organization
2014	Organisation for Economic Co-operation and Development
2013	Ministry of Health of Greece
2011	Research Triangle Institute International

PUBLICATIONS

PEER-REVIEWED ARTICLES

- Tu SS, Freeman N, Teng TW, Feldman WB, Kesselheim AS, Parton J, **Wouters OJ** (2026). Patents on small-molecule drugs approved by the US Food and Drug Administration, 1990-2019. *JAMA* (in press).
- Vogel M, **Wouters OJ** (2026). Policy and design considerations for most-favored-nation drug pricing. *JAMA Internal Medicine* (in press).
- Papanicolas I, **Wouters OJ**, Sawaya T, Han J, Wei J, Naci H (2026). [Review times for new drugs and submission delays among the FDA and 4 international regulators, 2014-2022](#). *Health Affairs*, 45(2): 184-192.
- Teng TW, Tu SS, Mooney H, Bendicksen L, Gabriele SME, **Wouters OJ**, Feldman WB (2026). [Tertiary patents on drugs approved by the FDA](#). *JAMA Health Forum*, 7(1): e255909.
- Vogel M, Feldman WB, Cowan Z, Rome BN, Chandra A, Kesselheim AS, **Wouters OJ** (2025). [Revenue differences between top-selling small-molecule drugs and biologics in Medicare](#). *JAMA Health Forum*, 6(10): e254720.
- Cherla A, Wagner AK, **Wouters OJ**, Woloshin S, Davis C, Mossialos E, Naci H (2025). [Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines](#). *JAMA*, 334(16): 1480-1482.
- Wouters OJ**, Denolle C, Wei J, Papanicolas I (2025). [Prices and affordability of essential medicines in 72 low-, middle-, and high-income markets](#). *JAMA Health Forum*, 6(8): e252043.

- Vokinger KN, Li G, **Wouters OJ** (2025). [The rise of drug innovation in China—implications for patient access in the United States and globally](#). *The New England Journal of Medicine*, 393(9): 839-841.
- Cherla A, Woloshin S, Wagner AK, **Wouters OJ**, Davis C, Mossialos E, Naci H (2025). [New cancer drug approvals: Less than half of important clinical trial uncertainties reported by the FDA to clinicians, 2019-22](#). *Health Affairs*, 44(7): 830-838.
- Wouters OJ**, Sullivan SD, Cousin EM, Gabriel N, Papanicolas I, Hernandez I (2025). [Drug prices negotiated by Medicare vs US net prices and prices in other countries](#). *JAMA*, 333(1): 85-87.
- Fuse Brown EC, **Wouters OJ**, Mehrotra A (2025). [Partnerships between pharmaceutical and telehealth companies—increasing access or driving inappropriate prescribing?](#) *The New England Journal of Medicine*, 392(12): 1148-1151.
- Chan MXJ, **Wouters OJ**, Chan HY, Terblanche P, Premisri N, Kim JH, Lim JCW, Tan-Koi WC, Jit M (2025). [Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective](#). *Vaccine*, 53: 127107.
- Wouters OJ**, Vogel M, Feldman WB, Beall RF, Kesselheim AS, Tu SS (2024). [Differential legal protections for biologics vs small-molecule drugs in the US](#). *JAMA*, 332(24): 2101-2108.
- Winner, AcademyHealth's Publication-of-the-Year Award
- Wouters OJ**, Kuha J (2024). [Low- and middle-income countries experienced delays accessing new essential medicines, 1982-2024](#). *Health Affairs*, 43(10): 1410-1419.
- Wouters OJ**, Naci H, Papanicolas I (2024). [Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies](#). *JAMA Internal Medicine*, 184(3): 328-330. [Reply](#): *JAMA Internal Medicine*, 2024; 184(7): 851.
- Wouters OJ**, Kesselheim AS, Kuha J, Luyten J (2024). [Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014](#). *Value in Health*, 27(10): 1373-1381.
- Sullivan SD, **Wouters OJ**, Cousin EM, Kirihenndige AS, Hernandez I (2024). [Integrating price benchmarks and comparative clinical effectiveness to inform the Medicare drug price negotiation program](#). *Value in Health*, 27(10): 1348-1357.
- Hernandez I, Cousin EM, **Wouters OJ**, Gabriel N, Cameron T, Sullivan SD (2024). [Medicare drug price negotiation: the complexities of selecting therapeutic alternatives for estimating comparative effectiveness](#). *Journal of Managed Care & Specialty Pharmacy*, 30(3): 218-225.
- Winner, \$25,000 prize for best paper in special issue on challenges in implementing the US Inflation Reduction Act

- Hernandez I, Cousin EM, **Wouters OJ**, Gabriel N, Cameron T, Sullivan SD (2024). [Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives](#). *Journal of Managed Care & Specialty Pharmacy*, 30(8): 762-772.
- Angelis A, Polyakov R, **Wouters OJ**, Torreele E, McKee M (2023). [High drug prices are not justified by industry's spending on research and development](#). *BMJ*, 380: e071710.
- Feldman WB, Tu SS, Alhiary R, Kesselheim AS, **Wouters OJ** (2023). [Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021](#). *JAMA*, 329(1): 87-89.
- Anderson M, **Wouters OJ**, Mossialos E (2023). [Transferable exclusivity extensions to stimulate antibiotic research and development: what is at stake?](#) *The Lancet Microbe*, 4(3): e127-e128.
- Vokinger KN, Perényi G, **Wouters OJ** (2023). [Investments in research and development for supplemental drug indications—implications for drug price negotiations](#). *JAMA Health Forum*, 4(9): e232798.
- van Kessel R, Forman R, Milstein R, Mastylak A, Czabanowska K, Cypionka T, Durand-Zaleski I, Hirche A, Kryszynska-Pisarek M, Maynou L, Roberts B, Torbica A, Vrangbæk K, Wang Y, **Wouters OJ**, Mossialos E (2023). [Divergent COVID-19 vaccine policies: policy mapping of ten European countries](#). *Vaccine*, 41(17): 2804-2810.
- Wouters OJ**, Forman R, Anderson M, Mossialos E, McKee M (2023). [The launch of the EU Health Emergency Preparedness and Response Authority \(HERA\): improving global pandemic preparedness?](#) *Health Policy*, 133: 104844.
- McKee M, **Wouters OJ** (2023). [The challenges of regulating artificial intelligence in healthcare](#). *International Journal of Health Policy and Management*, 12: 7261.
- Wouters OJ**, Feldman WB, Tu SS (2022). [Product hopping in the drug industry — lessons from albuterol](#). *The New England Journal of Medicine*, 387(13): 1153-1156.
- Wouters OJ**, Berenbrok LA, He M, Li Y, Hernandez I (2022). [Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018](#). *JAMA Network Open*, 5(9): e2218623.
- Wouters OJ**, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M (2021). [Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment](#). *The Lancet*, 397(10278): 1023-1034.
- Accompanied by [editorial](#) from *The Lancet* Editorial Board
 - Media coverage from Agence France-Presse, BBC, Bloomberg, CNN, Der Spiegel, The Guardian, The Huffington Post, O Globo, The New York Times, and Sky News
- Jit M, Ananthakrishnan A, McKee M, **Wouters OJ**, Beutels P, Teerawattananon Y (2021). [Multi-country collaboration in responding to global infectious disease threats: Lessons for Europe from the COVID-19 pandemic](#). *The Lancet Regional Health Europe*, 9: 100221.

- Wenham C, **Wouters OJ**, Jones C, Juma PA, Mijumbi-Deve RM, Sobngwi-Tambekou JL, Parkhurst J (2021). [Measuring health science research and development in Africa: Mapping the available data](#). *Health Research Policy and Systems*, 19: 142.
- Shi W, **Wouters OJ**, Liu G, Mossialos E, Yang X (2020). [Association between provincial income levels and drug prices in China over the period 2010-2017](#). *Social Science & Medicine*, 263: 1-10.
- Wouters OJ** (2020). [Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the United States, 1999-2018](#). *JAMA Internal Medicine*, 180(5): 688-697.
- Accompanied by [editorial](#) from Robert Steinbrook (Editor at Large, *JAMA Internal Medicine*)
 - Cited by Senator Bernie Sanders (I-VT) in an [op-ed](#) in The Guardian
 - Media coverage from Forbes, The New York Times, and STAT News
- Wouters OJ**, McKee M, Luyten J (2020). [Estimated research and development investment needed to bring a new medicine to market, 2009-2018](#). *JAMA*, 323(9): 844-853. [Reply: JAMA](#), 2020; 324(5): 518. Correction: *JAMA*, 2022; 328(11): 1110.
- Accompanied by editorials from [Gregory Curfman](#) (Deputy Editor, *JAMA*), [David Cutler](#) (Professor, Harvard University), and [Kenneth Frazier](#) (former CEO, Merck & Co.)
 - Media coverage from BBC, New York Times, STAT News, and Washington Post
- Wouters OJ**, Sandberg DM, Pillay A, Kanavos PG (2019). [The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period](#). *Social Science & Medicine*, 220: 362-370.
- Wouters OJ**, Kanavos PG, McKee M (2017). [Comparing generic drug markets in Europe and the United States: Prices, volumes, and spending](#). *The Milbank Quarterly*, 95(3): 554-601.
- Most read peer-reviewed study of 2017 in *The Milbank Quarterly*
- Naci H, **Wouters OJ**, Gupta R, Ioannidis JPA (2017). [Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval](#). *The Milbank Quarterly*, 95(2): 261-290.
- Wouters OJ**, Kanavos PG (2017). [A comparison of generic drug prices in seven European countries: A methodological analysis](#). *BMC Health Services Research*, 17(1): 242.
- Wouters OJ**, Cylus J, Yang W, Thomson S, McKee M (2016). [Medical savings accounts: Assessing their impact on efficiency, equity, and financial protection in health care](#). *Health Economics, Policy and Law*, 11(3): 321-335.
- Naci H, Lehman R, **Wouters OJ**, Goldacre B, Yudkin JS (2015). [Rethinking the appraisal and approval of drugs for type 2 diabetes](#). *BMJ*, 351: h5260.

- Wouters OJ**, Kanavos PG (2015). [Transitioning to a national health system in Cyprus: A stakeholder analysis of pharmaceutical policy reform](#). *Bulletin of the World Health Organization*, 93(9): 606-613.
- Wouters OJ**, O'Donoghue DJ, Ritchie J, Kanavos PG, Narva AS (2015). [Early chronic kidney disease: Diagnosis, management, and models of care](#). *Nature Reviews Nephrology*, 11(8): 491-502.
- Wouters OJ**, Naci H, Samani NJ (2015). [QALYs in cost-effectiveness analysis: An overview for cardiologists](#). *Heart*, 101(23): 1868-1873.
- Chambers JD, Naci H, **Wouters OJ**, Pyo J, Gunjal S, Kennedy IR, Hoey MG, Winn A, Neumann PJ (2015). [An assessment of the methodological quality of published network meta-analyses: A systematic review](#). *PLOS ONE*, 10(4): e0121715. Correction: *PLOS ONE*, 2015; 10(7): e0131953.
- Wouters OJ**, Downs PW, Zoerhoff KL, Crowley KR, Frawley H, Einberg J, Chu BK, Brady MA, Oscar R, Jeudi M, Desormeaux A-M, Coly K, Direny AN, Thakur GD, Pokharel RK, Sharma S, Raman DP, Sesay S, Sonnie M, Kilembe B, Mwingira U, Yajima A (2014). [Resource planning for neglected tropical disease \(NTD\) control programs: Feasibility study of the Tool for Integrated Planning and Costing \(TIPAC\)](#). *PLOS Neglected Tropical Diseases*, 8(2): e2619.

EDITORIALS & INVITED PAPERS

- Vogel M, Rangaraj S, **Wouters OJ** (2026). [The Trump administration's deals with pharma: Policy progress or political theater?](#) *Health Affairs Forefront*.
<https://doi.org/10.1377/forefront.20260724.788858>
- Singh Y, Reddy M, Mehta N, Rooke-Ley H, **Wouters OJ**, Fuse Brown EC (2025). [Unpacking private equity investments in drug industry third-party entities](#). *Health Affairs Forefront*.
<https://doi.org/10.1377/forefront.20251203.568413>
- Wouters OJ**, Kesselheim AS (2024). [Quantifying research and development expenditures in the drug industry](#). *JAMA Network Open*, 7(6): e2415407.
- Wouters OJ** (2024). [Lobbying in US health care—lessons from the field of oncology](#). *Journal of the National Comprehensive Cancer Network*, 22(4): 275-276.
- Hernandez I, **Wouters OJ**, Cousin EM, Kirihennedige AS, Sullivan SD (2024). [Interpreting the first round of maximum fair prices negotiated by Medicare for drugs](#). *Health Affairs Forefront*. <https://doi.org/10.1377/forefront.20240830.863408>.

Van Schalkwyk MCI, Jarman H, Hervey T, **Wouters OJ**, Barlow P, McKee M (2020). [Risks to health and the NHS in the post-Brexit era](#). *BMJ*, 369: m2307.

Wouters OJ, Hervey T, McKee M (2020). [Brexit and the European Medicines Agency—What next for the agency and UK drug regulators?](#) *JAMA Health Forum*, 1(2): e200135.

Luyten J, McKee M, **Wouters OJ** (2020). [How much does it cost to research and develop a new medicine?](#) [in Dutch]. *Nederlands Tijdschrift voor Geneeskunde*.

Wouters OJ, McKee M (2017). [Private financing of health care in times of economic crisis: A review of the evidence](#). *Global Policy*, 8(s2): 23-29.

Kanavos PG, **Wouters OJ** (2017). [Health care after the Great Recession: Financing options for sustainable and high-quality health systems](#). *Global Policy*, 8(s2): 5-6.

AMICUS BRIEFS, BOOK CHAPTERS & REPORTS

Carrier MA, Duan C, Tu SS, Kesselheim AS, et al (2026). [Brief of 76 scholars of law, business, economics, and medicine as amici curiae in support of petitioners, Hikma Pharmaceuticals v. Amarin Pharma, Inc. et al](#). (Case No. 24-889).

Anderson G, Carrier M, Chao B, Cheng T, Cohen RT, Darrow JJ, Duan C, Feldman W, Grimmelmann J, Gupta R, Hall BH, Heled Y, Frech HE, Kesselheim AS, Lemley MA, Liebesman YJ, Lockridge LAW, Luo J, Morten CJ, Ochoa T, Radomski T, Rome B, Ross J, Sadreameli C, Sarpawari A, Sinha MS, Stein D, Tu SS, Vertinsky L, **Wouters OJ** (2025). [Brief of 30 scholars of law, economics, and medicine as amici curiae in support of the petition for writ of certiorari to the United States Court of Appeals for the Federal Circuit in “Hikma Pharmaceuticals \(Petitioners\) v. Amarin Pharmaceuticals \(Respondents\)”](#) (Case No. 24-889).

Feldman WB, Kesselheim AS, Tu SS, Avorn J, Beall RF, Cohen RT, Gupta R, Radomski TR, Ramachandran R, Redberg RF, Rome BN, Ross J, Sadreameli SC, **Wouters OJ** (2025). [Motion by 14 professors of medicine and law for leave to file amicus curiae in support of defendants-appellees’ response to appellants’ petition for rehearing en banc in “Teva Branded Pharmaceutical Products R&D, Inc. \(Plaintiff-Appellant\) v. Amneal Pharmaceuticals of New York, LLC \(Defendant-Appellee\)”](#) (Case No. 24-1936, on appeal from the United States District Court for the District of New Jersey, Civil Action No. 23-cv-2094).

Feldman WB, Kesselheim AS, Tu SS, Avorn J, Beall RF, Cohen RT, Gupta R, Radomski TR, Ramachandran R, Redberg RF, Rome BN, Ross J, Sadreameli SC, **Wouters OJ** (2024). [Amicus brief in support of defendant-appellee in “Teva Branded Pharmaceutical Products R&D, Inc. \(Plaintiff-Appellant\) v. Amneal Pharmaceuticals of New York, LLC \(Defendant-Appellee\)”](#) (Case No. 24-1936, on appeal from the United States District Court for the District of New Jersey, Civil Action No. 23-cv-2094).

Jones CM, Ankotche A, Canner E, Habboubi F, Hadis M, Hedquist A, Juma PA, Keadiretse D, Masupe T, Mijumbi R, Mutombo N, Rakotobe AA, Sobngwi-Tambekou J, Welwean A, **Wouters OJ**, Wenham C, Parkhurst J (2021). [Strengthening national health research systems](#)

[in Africa: lessons and insights from across the continent](#). London: LSE Health.
<https://doi.org/10.6084/m9.figshare.14039807>

Wouters OJ (2018). [Essays on prices, volumes, and policies in generic drug markets in high- and middle-income countries](#). Ph.D. thesis, Department of Social Policy, London School of Economics and Political Science, 275 p.

Laviolette L, Gopalan S, Elder LK, **Wouters OJ** (2016). [Incentivizing nutrition: Incentive mechanisms to accelerate improved nutrition outcomes](#). The World Bank, Washington, DC, 76 p.

Laviolette L, Gopalan S, Elder LK, **Wouters OJ** (2016). [Incentivizing nutrition: How to apply incentive mechanisms to accelerate improved nutrition outcomes \(A practitioner's compendium\)](#). The World Bank, Washington, DC, 56 p.

Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Gerkens S, Henschke C, Hislop J, Jommi C, Kaitelidou D, Kawalec P, Keskimäki I, Kroneman M, Lopez Bastida J, Pita Barros P, Ramsberg J, Schneider P, Spillane S, Vogler S, Vuorenkoski L, Wallach Kildemoes H, **Wouters OJ**, Busse R (2016). [Pharmaceutical regulation in 15 European countries: Review](#). *Health Systems in Transition*, 18(5): 1-122.

Cylus J, **Wouters OJ**, Kanavos P (2016). [Chapter 9. Understanding the role of governance in the pharmaceutical sector: From laboratory to patient](#). In: Greer S, Wismar M, Figueras J (eds.) *Strengthening Health System Governance: Better Policies, Stronger Performance*. European Observatory on Health Systems and Policies. Open University Press: Maidenhead, UK. pp. 173-185.

Kanavos P, **Wouters OJ** (2014). [Pharmaceutical policies in Cyprus: A review of the current system and future options](#). Ministry of Health, Nicosia, Republic of Cyprus. 64 p.

Kanavos P, **Wouters OJ** (2014). [Pharmaceutical parallel trade: Legal, policy, and economic issues](#). In: Culyer AJ (ed.), *Encyclopedia of Health Economics*, Vol. 3, pp. 20-28. Oxford: Elsevier.

Kanavos P, **Wouters OJ** (2014). Competition issues in the distribution of pharmaceuticals [in [English](#) and [French](#)]. Directorate for Financial and Enterprise Affairs, Organisation for Economic Co-operation and Development. Policy brief for the *OECD Global Forum on Competition*. Paris, France. 9 p.

SELECTED PRESENTATIONS

Wouters OJ (2025). Timing of New Drug Launches in 90 Low-, Middle-, and High-Income Countries: A Retrospective Analysis of Data from 1982 to 2024. Speaker, Science for Health Systems Conference, 30 October 2025. St. Louis, MO, USA.

- Wouters OJ** (2025). Low- and middle-income countries experienced delays accessing new essential medicines, 1982-2024. Speaker, AcademyHealth Annual Research Meeting, 8 June 2025. Minneapolis, MN, USA.
- Wouters OJ** (2024). Low- and middle-income countries experienced delays accessing new essential medicines, 1982-2024. Invited speaker, *Health Affairs* Event, Journal Club, 21 October 2024. Washington, DC, USA (delivered virtually).
- Wouters OJ**, Shadlen K, Wei J, Papanicolas I (2024). Post-patent competition in pharmaceuticals: a global perspective. Speaker, 19th Annual Conference, European Policy for Intellectual Property Association, 11 September 2024. Florence, Italy.
- Wouters OJ** (2024). Why are drug prices so high and what can we do about it? The US in global perspective. Invited presentation, Center for the Evaluation of Value and Risk in Health (CEVR), Tufts University, 23 July 2024. Boston, MA, USA.
- Wouters OJ** (2022). Sales revenues in the pharmaceutical industry for new therapeutic agents approved from 1995 to 2014. Invited presentation, Program on Regulation, Therapeutics, and Law (PORTAL), Harvard University, 4 March 2022. Boston, MA, USA (delivered virtually).
- Hernandez I, Berenbrok L, He M, Li Y, **Wouters OJ** (2022). Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018. Poster presentation, AcademyHealth Annual Research Meeting, 5 June 2022. Washington, DC, USA.
- Wouters OJ** (2021). Challenges in ensuring global access to COVID-19 vaccines. Invited speaker, Blavatnik School of Government, University of Oxford, 12 May 2021. Oxford, UK.
- Wouters OJ** (2021). Challenges in ensuring global access to COVID-19 vaccines. Invited speaker, British Medical Association, 5 May 2021. London, UK.
- Wouters OJ** (2021). [How to make COVID-19 vaccination a success? Policy priorities and implementation from Israel and around the world.](#) Invited panelist, LSE Institute of Global Affairs, 26 January 2021. London, UK.
- Wouters OJ** (2019). What is the price impact of tendering for medicines by therapeutic class? A difference-in-differences estimation. Speaker (conference paper). Health Economists' Study Group Summer Meeting, 5 July 2019. University of East Anglia, Norwich, UK.
- Wouters OJ**, Wenham C, Parkhurst J (2019). Health sciences research in Africa: An empirical analysis. Invited speaker and panelist, DELTAS Africa Scientific Conference, 17 July 2019. Dakar, Senegal.
- Wouters OJ** (2018). Analyzing the impact of changes to pharmaceutical policies on medicine prices and demand in South Africa. Invited participant, Peking University, UK-China Workshop on the Economic Analysis of Large Medical Databases, 31 August 2018. Beijing, China.

Wouters OJ (2016). Incentive mechanisms for nutrition: What does the evidence tell us? Invited speaker, The World Bank, Workshop on Incentivizing Nutrition, 4 May 2016. Washington, DC, USA.

Wouters OJ, Kanavos PG (2015). Transitioning to a national health system in the Republic of Cyprus: A stakeholder analysis of pharmaceutical policy reform. Speaker, 3rd International Pharmaceutical Pricing and Reimbursement Information Conference. 13 October 2015. Vienna, Austria.

SELECTED MEDIA COVERAGE

STAT News. [Recent pharma-telehealth partnerships feel 'black boxy,' and why that's problematic](#), 26 March 2025 (Research referenced and quoted in Q&A session).

The New York Times. [US unveils price limits for 10 costly or common medications](#), 15 August 2024 (Research referenced).

NPR. [Could better asthma inhalers help patients, and the planet too?](#), 6 May 2024 (Research referenced).

The New York Times. [Six reasons drug prices are so high in the US](#), 17 January 2024 (Research referenced).

The Economist. [The National Health Service has a new drugs deal](#), 23 November 2023 (Quoted).

Politico. [The real reason Europe's medicines industry is dying](#), 25 April 2023 (Research referenced and quoted).

STAT News. [Here's why there aren't many cheap, generic versions of pricey inhalers](#), 16 March 2023 (Research referenced).

STAT News. [Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn't affect prices](#), 10 March 2023 (Research referenced and quoted).

Financial Times. [Drugmakers demand big cut in Britain's medicines levy](#), 27 February 2023 (Quoted).

TIME Magazine. [Big pharma's patent abuses are fueling the drug pricing crisis](#), 24 February 2023 (Research referenced).

The BMJ. [Licensing deal for cancer drug will increase access in low and middle income countries](#), 21 October 2022 (Quoted).

WIRED. [Big pharma says drug prices reflect R&D costs. Researchers call BS](#), 13 October 2022 (Research referenced and quoted).

- The New York Times. [The long, long wait for a diabetes cure](#), 9 August 2022 (Research referenced).
- The Washington Post. [Drug companies are warning that pricing reform spells doom. Don't fall for it](#), 8 August 2022 (Research referenced).
- Financial Times. [Nations urged to waive vaccine patents while drugmakers say rules are fair](#), 16 June 2022 (Quoted).
- The Lancet Infectious Diseases. [Booster shots for COVID-19—the debate continues](#), 1 October 2021 (Quoted).
- Bloomberg News. [When lifesaving vaccines become profit machines for drugmakers](#), 6 July 2021 (Research referenced).
- The Lancet Infectious Diseases. [Global COVID-19 vaccine inequity](#), 1 July 2021 (Quoted).
- BBC Radio 4. [Marvellous medicines](#), 14 June 2021 (Research referenced in this broadcast about drug discovery and development).
- Financial Times. [Biogen's \\$56,000-a-year Alzheimer's drug reignites US debate over costs](#), 8 June 2021 (Quoted).
- The Lancet Respiratory Medicine. [Ensuring fair distribution of COVID-19 vaccines: is an intellectual waiver the answer?](#), 21 May 2021 (Quoted).
- Forbes. [Why is healthcare so expensive? Blame the lobbyists](#), 9 April 2021 (Research referenced).
- The New York Times. [India cuts back on vaccine exports as infections surge at home](#), 25 March 2021 (Research referenced and quoted).
- The Lancet Respiratory Medicine. [Challenges in the rollout of COVID-19 vaccines worldwide](#), 5 March 2021 (Research referenced and quoted).
- Der Spiegel. [There would be enough for everyone—If rich countries would share](#) (in German), 26 February 2021 (Research referenced).
- BBC. [Covid-19 pandemic: Warning vaccine roll-out risks prolonging crisis](#), 13 February 2021 (Research referenced and quoted).
- Sky News. [COVID-19: Vaccine nationalism, high prices and supply chain issues slowing worldwide coronavirus inoculation, say scientists](#), 13 February 2021 (Research referenced and quoted).
- The Guardian. [No end to Covid pandemic without equal access to vaccine, experts say](#), 13 February 2021 (Research referenced and quoted).

TV interviews in February, March, and April 2021 about our study in [*The Lancet*](#) with BBC Business News, [BBC World News](#), Canadian Broadcasting Corporation, Scottish Television, [Sky News](#), and ZDF (German public broadcaster).

Radio interviews in February 2021 about our study in [*The Lancet*](#) with BBC 5 Live Breakfast, BBC Newshour, BBC World Service, LBC, and Times Radio.

The New York Times. [Want Vaccines Fast? Suspend Intellectual Property Rights](#), 7 December 2020 (Research referenced).

Science. [Scientists fear no-deal Brexit as deadline looms](#), 1 December 2020 (Quoted).

STAT News. [First-of-its-kind examination shows how widely pharma showers campaign cash at the state level](#), 15 October 2020 (Research referenced).

STAT News. [Pharma is showering Congress with cash, even as drug makers race to fight the coronavirus](#), 10 August 2020 (Research referenced and quoted).

The New York Times. [Indian billionaires bet big on head start in coronavirus vaccine race](#), 1 August 2020 (Quoted).

Foreign Affairs. [Drugs and vaccines are coming—But to whom?](#), 19 May 2020 (Research referenced).

Kaiser Health News. [Senators who led pharma-friendly patent reform also prime targets for pharma cash](#), 24 March 2020 (Research referenced).

Nature Reviews Drug Discovery. [\\$1.3 billion per drug?](#), 11 March 2020 (Research referenced).

STAT News. [New estimate says developing a drug costs \\$1.3 billion, which is a lot, but less than companies often say](#), 3 March 2020 (Research referenced and quoted).

Bloomberg News. [When Cancer Treatments Fail, Italy Wants Money Back](#), 15 Jan. 2016 (Quoted).

TEACHING

Course Convenor (London School of Economics)

Global Access to Medicines (2022–2024)
Pharmaceutical Economics and Policy (2022)

Seminar Leader (London School of Economics)

Applied Regression Analysis (2016)
Computing Packages for Applied Analysis: Stata (2016–2017)
Economic Analysis for Health Policy in Low- and Middle-Income Countries (2019–2020)
Health and Social Care Policy (2014)
Health Care Economic Evaluation (2018–2019)

Intermediate Quantitative Analysis (2015–2016)
Introduction to Quantitative Analysis (2014 and 2016)
Pharmaceutical Economics and Policy (2019–2024)
Principles of Health Technology Assessment (2020–2024)

Guest Lectures

Colgate University (2022–2023, graduate course)
King's College London (2020, undergraduate course)
Georgia State University College of Law (2024, law school course)
University of California, San Diego (2022–2023, graduate course)
University College London (2020 and 2023, graduate course)
University of Oxford (2021, graduate course)
University of Washington (2023 and 2025, graduate course)
West Virginia University College of Law (2024, law school course)

Teaching Qualification

Postgraduate Certificate in Higher Education, London School of Economics (2020)

PhD Supervision

Rasha Alhiary (2025–present, supervisor, Brown University)
Avi Cherla (2021–2026, secondary supervisor, London School of Economics)
Kristina Jenei (2022–2026, secondary supervisor, London School of Economics)
Leonhard Kersten (2025, member of PhD jury, Université Sorbonne Paris Nord, France)
Lars Van Cutsem (2023, visiting PhD student, KU Leuven, Belgium)

International Advisory Roles

[Commissioner](#), The Lancet Commission on Essential Medicines (2025–2027)
Member, International Advisory Board, MSc Global Health, KU Leuven, Belgium (2023–present)

PROFESSIONAL SERVICE

Recognitions

[Distinguished Reviewer](#), JAMA Internal Medicine (2024–present)
Top-graded peer reviewer, Annals of Internal Medicine (2016–2018 and 2020)
Top-graded peer reviewer, JAMA (2023)
Top-graded peer reviewer, JAMA Internal Medicine (2023)

Editorial Positions

Editorial Fellow, Health Affairs Scholar (2026–present)
Guest Academic Editor, PLOS Medicine (2025)
Academic Editor, PLOS Global Public Health (2024–present)

Guest Academic Editor, PLOS ONE (2020–2021)
Guest Editor (with Panos G. Kanavos), Global Policy (2017)

Ad Hoc Peer Reviewer (Journals)

Annals of Internal Medicine
BMC Health Services Research
BMJ
BMJ Global Health
BMJ Open
Bulletin of the World Health Organization
Clinical Trials
Cost Effectiveness and Resource Allocation
Drug Discovery Today
EClinicalMedicine
European Journal of Health Economics
Expert Review of Anti-Infective Therapy
Expert Review of Pharmacoeconomics & Outcomes Research
Family Medicine and Community Health
Globalization and Health
Health Affairs
Health Affairs Scholar
Health Economics
Health Policy
Health Policy and Planning
Health Policy and Technology
Health Services Research
Inquiry
International Journal of Clinical Practice
International Journal of Health Policy and Management
International Journal of Health Services
JAMA
JAMA Dermatology
JAMA Health Forum
JAMA Internal Medicine
JAMA Network Open
JAMA Psychiatry
Journal of Acquired Immune Deficiency Syndromes
Journal of Clinical Oncology
Journal of Development Studies
Journal of Globalization and Development
Journal of the Royal Society of Medicine
The Lancet
The Lancet Public Health
The Lancet Regional Health Europe
The Lancet Regional Health Western Pacific
The Milbank Quarterly
Nature Communications

Nephrology
Open Heart
PLOS Global Public Health
PLOS Medicine
PLOS ONE
PNAS Nexus
Saudi Pharmaceutical Journal
Social Science & Medicine
Vaccine
Value in Health
Value in Health Regional Issues
World Medical & Health Policy

Grant Reviewer

Economic and Social Research Council (part of United Kingdom Research and Innovation)
Swiss National Science Foundation

Professional Membership

AcademyHealth (Member, Advisory Committee, Global Health and Health Care Interest Group)
American Society of Health Economists
Health Economists' Study Group
Higher Education Academy (Fellow)
International Society for Pharmacoeconomics and Outcomes Research